Better treatment options for people affected by triple negative breast cancer
The goal of the PERSEVERE clinical trial is to find better treatment options for women affected by triple negative breast cancer.
Specifically, we’re investigating the use of certain medication combinations or a standard treatment approach based on:
- Presence of cancer cell pieces, known as circulating tumor DNA (ctDNA) in your blood (liquid biopsy); and
- Identification of genetic differences in your tumor.
Read on to learn why this study is needed, and what to expect if you volunteer to participate.